Polymyxin B (sulfate): Precision Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a crystalline polypeptide antibiotic mixture, principally composed of B1 and B2 isoforms, derived from Bacillus polymyxa (APExBIO, product page). It exhibits potent, concentration-dependent bactericidal action against major multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa (Li et al., 2023, DOI). The compound acts by disrupting bacterial membranes via cationic detergent properties. Preclinical models confirm a dose-dependent survival benefit in bacteremia and rapid reduction in bacterial load. However, its clinical use is bounded by nephrotoxicity and neurotoxicity risks (FDA label, FDA).

Biological Rationale

Polymyxin B (sulfate) targets Gram-negative bacteria with a high degree of selectivity. It is especially effective against organisms with outer membranes rich in lipopolysaccharides (LPS), such as Pseudomonas aeruginosa and Acinetobacter baumannii. The compound’s amphipathic structure enables strong electrostatic interactions with negatively charged LPS, circumventing common resistance mechanisms found in carbapenem-resistant strains (Poirel et al., 2017, DOI).

Beyond its antimicrobial effect, Polymyxin B (sulfate) has been shown in vitro to modulate human dendritic cell maturation, upregulating co-stimulatory molecules (CD86, HLA class I/II) and activating ERK1/2 and IκB-α/NF-κB pathways (APExBIO, product data).

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B operates as a cationic detergent. The positively charged peptide rings bind to the anionic lipid A moiety of LPS in the outer membrane, displacing Ca²⁺ and Mg²⁺ ions. This disrupts membrane integrity, increases permeability, and leads to leakage of intracellular contents, culminating in cell lysis and death (Velkov et al., 2019, DOI).

At the molecular level, exposure to 2 mg/ml Polymyxin B in phosphate-buffered saline (PBS, pH 7.2) results in rapid bactericidal activity within 1–2 hours against susceptible strains (APExBIO). The compound’s effects extend to immune modulation, including ERK1/2 and NF-κB pathway activation, which can influence host-pathogen interactions and inflammation (see also Polymyxin B Sulfate: Advanced Insights into Immune Modula...; this article further details quantitative immune pathway activation, updating prior overviews).

Evidence & Benchmarks

• Polymyxin B (sulfate) exhibits ≥95% purity by HPLC under standard storage (−20°C), as tested in APExBIO’s C3090 kit (product page).
• In vitro, 2 mg/ml in PBS (pH 7.2) is the solubility limit, suitable for most bactericidal and immune assays (APExBIO technical data).
• Dose-dependent survival benefit in bacteremia mouse models demonstrated (significant at p < 0.01) after intraperitoneal administration, with rapid bacterial clearance post-infection (bioRxiv preprint, Table 2).
• Promotes dendritic cell maturation in vitro by upregulation of CD86, HLA class I/II, and increased ERK1/2, IκB-α/NF-κB signaling (bioRxiv preprint, Figure 3).
• Active primarily against Gram-negative organisms, with limited or no effect on most Gram-positive species and fungi (Poirel et al., 2017, DOI).
• Nephrotoxicity and neurotoxicity observed in clinical use, especially at higher doses or prolonged exposure (FDA label, FDA).

For advanced workflows, see also Polymyxin B Sulfate: Advanced Workflows for Gram-Negative...; this guide focuses on protocol troubleshooting, while our article provides updated molecular benchmarks.

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is indicated for laboratory study of multidrug-resistant Gram-negative infections, bacteremia, and urinary tract infection models. It is also used for dendritic cell maturation assays and host-pathogen interaction studies. The compound is not broadly effective against Gram-positive bacteria or most fungi. Misapplication can result in misleading conclusions about spectrum of activity or immune effects.

Common Pitfalls or Misconceptions

• Polymyxin B (sulfate) is not effective against most Gram-positive bacteria or anaerobes.
• It does not reliably prevent or treat infections caused by fungi.
• Long-term storage of prepared solutions (>1 week, even at −20°C) decreases activity; fresh solutions are recommended.
• In vitro immune modulation does not always predict in vivo outcomes; results must be contextualized.
• Nephrotoxicity and neurotoxicity risks limit use in clinical settings and require careful dose titration in animal studies.

This article expands upon Polymyxin B (sulfate): Mechanisms and Advanced Research Applications by integrating new data on immune signaling and updated toxicity benchmarks.

Workflow Integration & Parameters

• Solubility: Up to 2 mg/ml in PBS (pH 7.2).
• Storage: −20°C for long-term powder; solutions for short-term (≤1 week) at 4°C or −20°C.
• Purity: ≥95% by HPLC (APExBIO).
• Molecular weight: 1301.6 (free base); formula: C56H98N16O13·H2SO4.
• Recommended Use: Dendritic cell maturation (0.5–2 mg/ml); Gram-negative bactericidal assays (0.5–2 mg/ml); in vivo models per protocol.

For advanced immunomodulation protocols, see Polymyxin B Sulfate: Innovations in Immunomodulation and ...; this resource emphasizes translational models, while the current article provides quantitative workflow recommendations.

Conclusion & Outlook

Polymyxin B (sulfate) from APExBIO is a validated, high-purity antibiotic for Gram-negative infection research and immune modulation studies. Its membrane-targeting mechanism, immune signaling effects, and well-characterized toxicity profile make it a benchmark reagent in both microbiology and immunology workflows. Continued research is needed to refine its use in translational models and to mitigate adverse effects. For detailed product specifications, consult the Polymyxin B (sulfate) C3090 kit documentation.